Clinical trials: Thrombotic Microangiopathies
ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.
- Trial name
- NCT01755429
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Purpura, Thrombocytopenic, Idiopathic
A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.
- Trial name
- NCT02403440
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).
- Trial name
- NCT00828750
- Testing
- Eltrombopag oral tablets
- Where
- 6 sites in Japan
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura
- Trial name
- NCT00508820
- Testing
- Romiplostim
- Volunteers
- 407 people
- Sponsor
- Amgen
Idiopathic Purpura
Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children
Idiopathic purpura fulminans by anti-protein S antibody is a very rare but potentially extremely serious entity. The data in the literature are poor with only isolated report boxes and a single series of less than 10 boxes.
- Trial name
- NCT04845113
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Thrombotic Thrombocytopenic Purpura
ADAMTS13 in Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy defined by the spontaneous formation of platelet thrombi in the microvessels.
- Trial name
- ADAMTS13 (NCT00426686)
- Where
- France
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Purpura, Thrombocytopenic, Idiopathic
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6…
- Trial name
- EIS2002 (NCT02334813)
- Testing
- Prednisone, Dexamethasone
- Volunteers
- 26 people
- Sponsor
- University Hospital, Essen
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2)…
- Trial name
- NCT05714969
- Testing
- TAK-755
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 29 people
- Sponsor
- Takeda
Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
The project was undertaking by Qilu Hospital of Shandong University and other 2 well-known hospitals in China. In order to report the efficacy and safety of rituximab combining with bortezomib for the treatment of adults with…
- Trial name
- NCT03443570
- Testing
- Rituximab, Bortezomib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong University
Thrombocytopenic Purpura
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.
- Trial name
- NCT00117143
- Testing
- Romiplostim
- Volunteers
- 16 people
- Sponsor
- Amgen
Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Severe Immune Cytopenia Registry Www.Sic-reg.Org
Prospective registry study for children and young adults with severe immune cytopenias (persisting/chronic immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome) to improve the management, facilitate the…
- Conditions
- Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, Evans Syndrome, Primary Immunodeficiency
- Trial name
- sic-reg (NCT03576742)
- Testing
- potential biomarkers
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Medical University of Graz
Immune Thrombocytopenia
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety…
- Trial name
- NCT02566603
- Testing
- PRTX-100
- Where
- 16 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Protalex, Inc.
Primary Immune Thrombocytopenia
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
- Trial name
- ADVANCE+ (NCT04225156)
- Testing
- efgartigimod
- Where
- 87 sites in United States, Austria and 16 more
- Volunteers
- 101 people
- Sponsor
- argenx
Immune Thrombocytopenia (ITP)
V-IMMUNE® for Immune Thrombocytopenia
This is a multicenter, prospective clinical trial evaluating the efficacy and safety of V-IMMUNE®, a 5% human normal immunoglobulin formulation administered intravenously, for the treatment of immune thrombocytopenia (ITP) in…
- Trial name
- TIP (NCT06962631)
- Testing
- 5% (5g/100 ml) intravenous immunoglobin
- Where
- 2 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
Immune Thrombocytopenia, Myelodysplastic Syndromes
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia, including immunodeficiencies, constitutional or…
- Trial name
- NCT03469661
- Where
- 6 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Primary Immune Thrombocytopenia (ITP)
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
This is a randomized controlled study of high-dose Dexamethasone combined with Orelabrutinib versus high-dose Dexamethasone combined with placebo in adult patients with newly diagnosed Primary Immune Thrombocytopenia.
- Trial name
- NCT07559331
- Testing
- High-Dose Dexamethasone Combined with Orelabrutinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Shandong University
Immune Thrombocytopenia (ITP)
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP.
- Trial name
- NCT07095127
- Testing
- NVG-2089
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nuvig Therapeutics, Inc.
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Idiopathic Thrombocytopenic Purpura (ITP)
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
The purpose of this research study is to compare the efficacy and safety of higher doses of rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine, and Prednisone) in patients with chronic…
- Trial name
- NCT00161564
- Testing
- Rituximab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Immune Thrombocytopenia (ITP)
Autoantibody Specificity and Response to IVIG in ITP
The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
- Trial name
- NCT01666795
- Where
- China
- Volunteers
- 672 people
- Sponsor
- Shandong University